The CSM in the UK noted that pharmacodynamic interactions have been identified between
triptans and
St John's wort (Hypericum perforatum) leading to an increased risk of adverse effects. This has been seen with other drugs with serotonergic effects, such as the
SSRIs.
The CSM suggest that patients taking
triptans should not take St John's wort preparations: the manufacturers generally advise caution, which seems prudent, see
serotonin syndrome.